Clinical Trials Browser

Interventional × ublituximab × 1 year × Clear all

NCT04624633 2026-02-25

Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

Phase 2 Active not recruiting

29 enrolled 9 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell